Thermo Fisher Scientific (TMO) Current Deferred Revenue (2009 - 2026)

Thermo Fisher Scientific has reported Current Deferred Revenue for 18 years, with the latest figure at $2.9 billion in Q2 2026.

• Current Deferred Revenue for Q2 2026 came in at $2.9 billion, up 4.03% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.9 billion (up 4.03% YoY), and the FY2025 annual result was $2.7 billion, down 4.98% from the prior year.
• Current Deferred Revenue steadied at $2.9 billion in Q2 2026, from $2.9 billion in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $2.9 billion in Q1 2026 and troughed at $2.5 billion in Q3 2023.
• A 5-year average of $2.7 billion and a median of $2.7 billion in 2023 frame the typical range for Current Deferred Revenue.
• The widest annual swing landed in 2022, when Current Deferred Revenue soared 105.66%; it then fell 7.28% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $2.6 billion in 2022, then grew by 3.38% to $2.7 billion in 2023, then gained by 6.06% to $2.9 billion in 2024, then declined by 4.98% to $2.7 billion in 2025, then advanced by 7.68% to $2.9 billion in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $2.9 billion in Q2 2026, $2.9 billion in Q1 2026, and $2.7 billion in Q4 2025.